Zehna Therapeutics is an early stage biotech company focused on developing novel small molecules targeting specific gut microbial pathways to treat chronic disease
Zehna Therapeutics is developing non-bacteriocidal inhibitors of selected gut microbial pathways clinically and mechanistically linked with chronic metabolic diseases. Our lead compounds inhibit the gut microbial enzyme CutC, preventing the conversion of dietary choline to trimethylamine (TMA) and subsequently to trimethylamine N-oxide (TMAO) within the host.
High systemic levels of TMAO have been linked to accelerated development of both cardiovascular and chronic kidney disease, as demonstrated in large-scale clinical cohort studies. Chronic Kidney Disease is our lead indication.
OUR BOARD OF DIRECTORS
Zehna Therapeutics to Present at Biotech Showcase™ 2023
Zehna Therapeutics will present at the Biotech Showcase 2023 conference being held in-person on January 9-11, 2023, at the Hilton San Francisco Union Square in San Francisco, California, and virtually on January 18-19, 2023Read More →
Goodwill Fuels Innovation
With scientists and physicians seamlessly collaborating to provide the best patient care, Cleveland Clinic has been the future of health care since 1921. The academic medical center has established a new standard in medical research, made possible through philanthropic efforts.Read More →
Inside the Minds of Bioleaders – Camilla Simpson Interview
Camilla Simpson has over two decades of business and strategy experience across a diverse group of organizations: from seed investments to public companies. Camilla has demonstrated a proven track record in delivering novel products for multiple disease indications to global markets in areas of high unmet medical need throughout her career.Read More →
Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulo…
Development Of A Gut Microbe–Targeted Nonlethal Therapeutic To Inhibit Thrombosis Potential